Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02947165 · ClinicalTrials.gov registry record · Phase 1
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT02947165 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 120 participants.
The verdict
NCT02947165, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.
Interventions
- DRUG PDR001
- DRUG NIS793
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-04-25 |
| Est. Completion | 2021-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02947165
The ClinicalTrials.gov registry entry for NCT02947165 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PDR001 is the first listed.
NCT02947165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02947165 about?
NCT02947165 is a clinical study titled "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.". To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.
What is the current status of trial NCT02947165?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2017-04-25. Estimated completion is 2021-06-18.
What interventions are being tested in trial NCT02947165?
The interventions under investigation include: PDR001 (DRUG), NIS793 (DRUG).
Who is sponsoring clinical trial NCT02947165?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.